{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:39Z","timestamp":1793727879081,"version":"4.6.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00198-025-07707-7","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:35:12Z","timestamp":1761892512000},"page":"319-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3800-8667","authenticated-orcid":false,"given":"Mohamed","family":"Abdalbary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mazen","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elaraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"6","key":"7707_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","volume":"94","author":"WHO","year":"1993","unstructured":"WHO (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):646\u2013650","journal-title":"Am J Med"},{"issue":"6","key":"7707_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH","year":"2001","unstructured":"NIH (2001) Consensus development panel on osteoporosis prevention, diagnosis, and therapy. Jama 285(6):785\u2013795","journal-title":"Jama"},{"issue":"3","key":"7707_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4103\/1319-2442.206439","volume":"28","author":"MS Najar","year":"2017","unstructured":"Najar MS, Mir MM, Muzamil M (2017) Prevalence of osteoporosis in patients with chronic kidney disease (stages 3\u20135) in comparison with age-and sex-matched controls: a study from Kashmir Valley Tertiary Care Center. Saudi J Kidney Dis Transpl 28(3):538","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"8","key":"7707_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3109\/0886022X.2013.815102","volume":"35","author":"H Aggarwal","year":"2013","unstructured":"Aggarwal H et al (2013) Bone mineral density in patients with predialysis chronic kidney disease. Ren Fail 35(8):1105\u20131111","journal-title":"Ren Fail"},{"issue":"11","key":"7707_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A et al (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166(11):818\u2013839","journal-title":"Ann Intern Med"},{"key":"7707_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update. Endocr Pract 26:1\u201346","journal-title":"Endocr Pract"},{"issue":"1","key":"7707_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2474-10-60","volume":"10","author":"G-S Huang","year":"2009","unstructured":"Huang G-S et al (2009) Factors associated with low bone mass in the hemodialysis patients\u2013a cross-sectional correlation study. BMC Musculoskelet Disord 10(1):1\u201310","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"7707_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1681\/ASN.2006050546","volume":"18","author":"LF Fried","year":"2007","unstructured":"Fried LF et al (2007) Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 18(1):282\u2013286","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"7707_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1001\/archinte.167.2.133","volume":"167","author":"KE Ensrud","year":"2007","unstructured":"Ensrud KE et al (2007) Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167(2):133\u2013139","journal-title":"Arch Intern Med"},{"issue":"7","key":"7707_CR10","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M et al (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70(7):1358\u20131366","journal-title":"Kidney Int"},{"issue":"4","key":"7707_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0272-6386(04)00958-8","volume":"44","author":"A Mittalhenkle","year":"2004","unstructured":"Mittalhenkle A, Gillen DL, Stehman-Breen CO (2004) Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 44(4):672\u2013679","journal-title":"Am J Kidney Dis"},{"key":"7707_CR12","doi-asserted-by":"crossref","unstructured":"Kini U,\u00a0Nandeesh B (2012) Physiology of bone formation, remodeling, and metabolism. In: Radionuclide and hybrid bone imaging. Springer, Berlin, Heidelberg, pp 29\u201357","DOI":"10.1007\/978-3-642-02400-9_2"},{"issue":"1","key":"7707_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","volume":"36","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel P et al (2021) European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5D. Nephrol Dial Transplant 36(1):42\u201359","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"7707_CR14","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1093\/ndt\/14.8.1922","volume":"14","author":"MW Taal","year":"1999","unstructured":"Taal MW et al (1999) Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 14(8):1922\u20131928","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"7707_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/kisup.2013.93","volume":"3","author":"JJ Kazama","year":"2013","unstructured":"Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int Suppl (2011) 3(5):446\u2013450","journal-title":"Kidney Int Suppl (2011)"},{"issue":"3","key":"7707_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1681\/ASN.2010121253","volume":"23","author":"HH Malluche","year":"2012","unstructured":"Malluche HH et al (2012) Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol 23(3):525\u2013532","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"7707_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jbmr.309","volume":"26","author":"HH Malluche","year":"2011","unstructured":"Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26(6):1368\u20131376","journal-title":"J Bone Miner Res"},{"issue":"6","key":"7707_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7326\/M17-2640","volume":"168","author":"M Ketteler","year":"2018","unstructured":"Ketteler M et al (2018) Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Ann Intern Med 168(6):422\u2013430","journal-title":"Ann Intern Med"},{"key":"7707_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab081","author":"R Neto","year":"2021","unstructured":"Neto R et al (2021) Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease stages 3 and 4. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfab081","journal-title":"Clin Kidney J"},{"issue":"2","key":"7707_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2015.156","volume":"88","author":"P Evenepoel","year":"2015","unstructured":"Evenepoel P, D\u2019haese P, Brandenburg V (2015) Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 88(2):235\u2013240","journal-title":"Kidney Int"},{"issue":"5\u20136","key":"7707_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s001090100226","volume":"79","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin in bone cell biology. J Mol Med 79(5\u20136):243\u2013253","journal-title":"J Mol Med"},{"issue":"3","key":"7707_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1359\/jbmr.090735","volume":"25","author":"C Tomiyama","year":"2010","unstructured":"Tomiyama C et al (2010) Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res 25(3):499\u2013504","journal-title":"J Bone Miner Res"},{"issue":"4","key":"7707_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174811","volume":"12","author":"FR Hernandes","year":"2017","unstructured":"Hernandes FR et al (2017) The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: a 12-month follow-up study. PLoS ONE 12(4):e0174811","journal-title":"PLoS ONE"},{"issue":"5","key":"7707_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/ki.1993.350","volume":"44","author":"AJ Hutchison","year":"1993","unstructured":"Hutchison AJ et al (1993) Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44(5):1071\u20131077","journal-title":"Kidney Int"},{"issue":"2","key":"7707_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","volume":"89","author":"TB Dr\u00fceke","year":"2016","unstructured":"Dr\u00fceke TB, Massy ZA (2016) Changing bone patterns with progression of chronic kidney disease. Kidney Int 89(2):289\u2013302","journal-title":"Kidney Int"},{"issue":"4","key":"7707_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM et al (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67(4):559\u2013566","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"7707_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40620-017-0397-7","volume":"30","author":"Z Massy","year":"2017","unstructured":"Massy Z, Drueke T (2017) Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. J Nephrol 30(5):629\u2013634","journal-title":"J Nephrol"},{"issue":"5","key":"7707_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/ndt\/11.5.813","volume":"11","author":"G Coen","year":"1996","unstructured":"Coen G et al (1996) Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 11(5):813\u2013819","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"7707_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5935\/0101-2800.20140042","volume":"36","author":"FC Barreto","year":"2014","unstructured":"Barreto FC et al (2014) Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. J Bras Nefrol 36(3):289\u2013296","journal-title":"J Bras Nefrol"},{"issue":"5","key":"7707_CR30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.ekir.2022.02.022","volume":"7","author":"A El-Husseini","year":"2022","unstructured":"El-Husseini A et al (2022) Low turnover renal osteodystrophy with abnormal bone quality and vascular calcification in patients with mild-to-moderate CKD. Kidney Int Rep 7(5):1016\u20131026","journal-title":"Kidney Int Rep"},{"key":"7707_CR31","doi-asserted-by":"crossref","unstructured":"Mohamed AE et al (2021) Progression of renal osteodystrophy and vascular calcifications in patients with CKD Stage II-IV:PO0590.\u00a0J Am Soc Nephrol\u00a032(10S):222","DOI":"10.1681\/ASN.20213210S1222a"},{"issue":"11","key":"7707_CR32","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J et al (2021) Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143(11):1157\u20131172","journal-title":"Circulation"},{"issue":"3","key":"7707_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/ki.1994.342","volume":"46","author":"P Kurz","year":"1994","unstructured":"Kurz P et al (1994) Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46(3):855\u2013861","journal-title":"Kidney Int"},{"issue":"7","key":"7707_CR34","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","volume":"15","author":"GM London","year":"2004","unstructured":"London GM et al (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15(7):1943\u20131951","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"7707_CR35","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1053\/j.ajkd.2008.06.024","volume":"52","author":"DV Barreto","year":"2008","unstructured":"Barreto DV et al (2008) Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis 52(6):1139\u20131150","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"7707_CR36","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/ndt\/gfq491","volume":"26","author":"G Asci","year":"2011","unstructured":"Asci G et al (2011) The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant 26(3):1010\u20131015","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"7707_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.kint.2021.04.043","volume":"100","author":"M Haarhaus","year":"2021","unstructured":"Haarhaus M, Evenepoel P (2021) Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int 100(3):546\u2013558","journal-title":"Kidney Int"},{"issue":"3","key":"7707_CR38","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.kint.2021.05.024","volume":"100","author":"SM Ott","year":"2021","unstructured":"Ott SM et al (2021) Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. Kidney Int 100(3):502\u2013505","journal-title":"Kidney Int"},{"issue":"6","key":"7707_CR39","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.kint.2021.09.011","volume":"100","author":"A El-Husseini","year":"2021","unstructured":"El-Husseini A et al (2021) Antiresorptives in patients with chronic kidney disease with adynamic bone: is absence of evidence of harm equal to no harm? Kidney Int 100(6):1341\u20131342","journal-title":"Kidney Int"},{"issue":"2","key":"7707_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron R, Kneissel M (2013) Wnt signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19(2):179\u2013192","journal-title":"Nat Med"},{"key":"7707_CR41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/bonekey.2015.36","volume":"4","author":"F Gori","year":"2015","unstructured":"Gori F et al (2015) A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures. BoneKEy Rep 4:669","journal-title":"BoneKEy Rep"},{"issue":"20","key":"7707_CR42","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X et al (2005) Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J Biol Chem 280(20):19883\u201319887","journal-title":"J Biol Chem"},{"key":"7707_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29\u201337","journal-title":"Bone"},{"key":"7707_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering7030088","author":"J Tyson","year":"2020","unstructured":"Tyson J et al (2020) Mechanisms of the osteogenic switch of smooth muscle cells in vascular calcification: WNT signaling, BMPs, mechanotransduction, and EndMT. Bioengineering. https:\/\/doi.org\/10.3390\/bioengineering7030088","journal-title":"Bioengineering"},{"issue":"6","key":"7707_CR45","doi-asserted-by":"publisher","first-page":"H2376","DOI":"10.1152\/ajpheart.01173.2003","volume":"287","author":"X Wang","year":"2004","unstructured":"Wang X et al (2004) LDL receptor-related protein LRP6 regulates proliferation and survival through the Wnt cascade in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 287(6):H2376\u2013H2383","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"12","key":"7707_CR46","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1128\/MCB.25.12.5022-5030.2005","volume":"25","author":"Z Wang","year":"2005","unstructured":"Wang Z et al (2005) Wnt7b activates canonical signaling in epithelial and vascular smooth muscle cells through interactions with Fzd1, Fzd10, and LRP5. Mol Cell Biol 25(12):5022\u20135030","journal-title":"Mol Cell Biol"},{"issue":"5","key":"7707_CR47","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00223-007-9073-6","volume":"81","author":"L Mikhaylova","year":"2007","unstructured":"Mikhaylova L, Malmquist J, Nurminskaya M (2007) Regulation of in vitro vascular calcification by BMP4, VEGF and Wnt3a. Calcif Tissue Int 81(5):372\u2013381","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"7707_CR48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1210\/jc.2013-2786","volume":"99","author":"D Cejka","year":"2014","unstructured":"Cejka D et al (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99(1):248\u2013255","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"7707_CR49","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.kint.2016.12.029","volume":"91","author":"FG Graciolli","year":"2017","unstructured":"Graciolli FG et al (2017) The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int 91(6):1436\u20131446","journal-title":"Kidney Int"},{"issue":"5","key":"7707_CR50","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.kint.2019.06.007","volume":"96","author":"M Ara\u00fajo","year":"2019","unstructured":"Ara\u00fajo M et al (2019) Comparison of serum levels with bone content and gene expression indicate a contradictory effect of kidney transplantation on sclerostin. Kidney Int 96(5):1100\u20131104","journal-title":"Kidney Int"},{"issue":"1","key":"7707_CR51","first-page":"1426","volume":"44","author":"Q Xiao","year":"2022","unstructured":"Xiao Q et al (2022) Sclerostin is involved in osteogenic transdifferentiation of vascular smooth muscle cells in chronic kidney disease-associated vascular calcification with non-canonical Wnt signaling. Ren Fail 44(1):1426\u20131442","journal-title":"Ren Fail"},{"issue":"3","key":"7707_CR52","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/ndt\/gfy129","volume":"34","author":"VM Brandenburg","year":"2019","unstructured":"Brandenburg VM et al (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34(3):408\u2013414","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"7707_CR53","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jbmr.4203","volume":"36","author":"ML Mace","year":"2021","unstructured":"Mace ML et al (2021) chronic kidney disease-induced vascular calcification impairs bone metabolism. J Bone Miner Res 36(3):510\u2013522","journal-title":"J Bone Miner Res"},{"key":"7707_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11120849","author":"ML Mace","year":"2021","unstructured":"Mace ML et al (2021) New insights to the crosstalk between vascular and bone tissue in chronic kidney disease-mineral and bone disorder. Metabolites. https:\/\/doi.org\/10.3390\/metabo11120849","journal-title":"Metabolites"},{"key":"7707_CR55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1471-2369-15-190","volume":"15","author":"FL Gon\u00e7alves","year":"2014","unstructured":"Gon\u00e7alves FL et al (2014) Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 15:190","journal-title":"BMC Nephrol"},{"issue":"3","key":"7707_CR56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000443845","volume":"132","author":"G Jean","year":"2016","unstructured":"Jean G et al (2016) High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron 132(3):181\u2013190","journal-title":"Nephron"},{"issue":"4","key":"7707_CR57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.33549\/physiolres.934034","volume":"68","author":"M Kalousov\u00e1","year":"2019","unstructured":"Kalousov\u00e1 M et al (2019) Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients: a prospective observational cohort study. Physiol Res 68(4):547\u2013558","journal-title":"Physiol Res"},{"issue":"2","key":"7707_CR58","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/ndt\/gfu301","volume":"30","author":"C Drechsler","year":"2015","unstructured":"Drechsler C et al (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30(2):288\u2013293","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"7707_CR59","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/0886022X.2020.1741386","volume":"42","author":"Y Zou","year":"2020","unstructured":"Zou Y et al (2020) Association of sclerostin with cardiovascular events and mortality in dialysis patients. Ren Fail 42(1):282\u2013288","journal-title":"Ren Fail"},{"issue":"11","key":"7707_CR60","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00198-022-06462-3","volume":"33","author":"M Abdalbary","year":"2022","unstructured":"Abdalbary M et al (2022) Management of osteoporosis in patients with chronic kidney disease. Osteoporos Int 33(11):2259\u20132274","journal-title":"Osteoporos Int"},{"issue":"7","key":"7707_CR61","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1161\/ATVBAHA.119.312371","volume":"39","author":"K Asadipooya","year":"2019","unstructured":"Asadipooya K, Weinstock A (2019) Cardiovascular outcomes of romosozumab and protective role of alendronate. Arterioscler Thromb Vasc Biol 39(7):1343\u20131350","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"7707_CR62","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"11","key":"7707_CR63","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/jbmr.4409","volume":"36","author":"JP Brown","year":"2021","unstructured":"Brown JP et al (2021) Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the active-controlled fracture study in postmenopausal women with osteoporosis at high risk (ARCH) trial. J Bone Miner Res 36(11):2139\u20132152","journal-title":"J Bone Miner Res"},{"issue":"10102","key":"7707_CR64","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390(10102):1585\u20131594","journal-title":"Lancet"},{"issue":"16","key":"7707_CR65","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543","journal-title":"N Engl J Med"},{"issue":"3","key":"7707_CR66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM et al (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34(3):419\u2013428","journal-title":"J Bone Miner Res"},{"issue":"8","key":"7707_CR67","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD et al (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37(8):1437\u20131445","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7707_CR68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","volume":"112","author":"T Saito","year":"2023","unstructured":"Saito T et al (2023) One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int 112(1):34\u201344","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 1","key":"7707_CR69","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/annrheumdis-2020-eular.4539","volume":"79","author":"P Miller","year":"2020","unstructured":"Miller P et al (2020) OP0297 Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. Ann Rheum Dis 79(Suppl 1):185\u2013185","journal-title":"Ann Rheum Dis"},{"key":"7707_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081660","author":"A Vestergaard Kvist","year":"2021","unstructured":"Vestergaard Kvist A et al (2021) Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system (FAERS). J Clin Med. https:\/\/doi.org\/10.3390\/jcm10081660","journal-title":"J Clin Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07707-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07707-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07707-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:05:19Z","timestamp":1772582719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07707-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7707"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07707-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}